May 11, 2010: Cultural Fluency: The HIV/AIDS Diversity Challenge
	May 14, 2010: The Role of Infrastructure Management in Reducing HIV Disparities in Clinical Settings
	May 18, 2010: Improving HAART Therapy for Minority Females Infected with HIV

Note: For the complete list and more information, please visit: www.nmaetc.org

Date: May 15-17
Location: Arlington, VA

Note: Voices is a forum for providers, such as nurses, social workers, physicians, program administrators, case managers, care coordinators, and consumers to come together for the only national conference dedicated to AIDS and women, children, youth, and families. Every year, Voices celebrates the hope brought about by advances in prevention and treatment while at the same time reminding conference goers and policy makers that making this hope a reality requires sustained commitment on the part of our country's residents and leadership. The conference is sponsored by the AIDS Alliance for Children, Youth, and Families.
Registration information and agenda can be found at: http://www.aids-alliance.org

Note: May 18 is HIV Vaccine Awareness Day (HVAD). This annual observance is a day to recognize and thank the thousands of volunteers, community members, health professionals, and scientists who are working together to find a safe and effective HIV vaccine. It is also a day to educate communities about the importance of preventive HIV vaccine research. In recognition of HIV Vaccine Awareness Day, community activities and media events are being held around the country. Learn more about resources and events at: http://www.niaid.nih.gov/news/events/hvad/Pages/default.aspx

Date: May 19th, 2010
Note: National Asian and Pacific Islander HIV/AIDS Awareness Day will take place on May 19. For more information and to learn about events planned for the day go to: http://aids.gov/awareness-days/national-asian-pacific-islander

FDA has approved a new dosing regimen for Kaletra (lopinavir/ritonavir) tablets and oral solution. Kaletra can be administered once daily (800/200 mg) in patients with less than three lopinavir resistance associated substitutions. Once daily administration of Katetra is not recommended for adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. Also, once daily administration of Kaletra is not recommended in pediatric patients.

The complete revised label is available at the FDA Web site: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA